

Laurus Labs Limited
Corporate Office
2nd Floor, Serene Chambers, Road No. 7
Banjara Hills, Hyderabad - 500034, Telangana, India
T +91 40 39804333 / 2342 0500 / 501
F +91 40 3980 4320



May 19, 2020

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS
--	---

Dear Sirs,


Sub: Press Release - Laurus Labs receives USFDA approvals for ANDAs TLE 400 and TLE 600 tablets

The Company is pleased to announce that it has received an approval from USFDA under PEPFAR (President's Emergency Plan for AIDS Relief) for two ANDAs (Abbreviated New Drug Application) TLE 400 (Tenofovir/ Lamivudine/ Efavirenz - 300/300/400mg) and TLE 600 (Tenofovir/ Lamivudine/ Efavirenz - 300/300/600mg) tablets.

A press release to this extent is also enclosed for your information and records.

Thanking you,

Yours sincerely,
For Laurus Labs Limited


G. Venkateswar Reddy
Company Secretary



Encl: As above

Laurus Labs receives USFDA approvals for ANDAs TLE₄₀₀ and TLE₆₀₀ tablets.

Hyderabad, May 19, 2020, Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010)

Laurus Labs Ltd is pleased to announce that the Company has received an approval from USFDA under PEPFAR (President's Emergency Plan for AIDS Relief) for two ANDAs (*Abbreviated New Drug Application*) TLE₄₀₀ (*Tenofovir/ Lamivudine/ Efavirenz - 300/300/400mg*) and TLE₆₀₀ (*Tenofovir/ Lamivudine/ Efavirenz - 300/300/600mg*) tablets.

Laurus Labs is one of the few players in the ARV segment to receive an approval for TLE₄₀₀ tablets. TLE₄₀₀ is one of the most preferred regimens in the ARV first line treatment. The Company already received WHO Pre-Qualification for TLE₄₀₀ (*Tenofovir/ Lamivudine/ Efavirenz - 300/300/400mg*)


These approvals enables Laurus Labs to launch both the products in several LMIC markets.

About Laurus Labs Limited

Laurus Labs is a leading research driven Pharmaceutical Manufacturing Company in India. We have grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma, and Gastroenterology. We are thriving on growth opportunities in formulation manufacturing to service all leading markets of North America, Europe and Low Middle-Income Countries (LMIC). We are driving growth opportunities in Contract Development and Manufacturing through our Synthesis business. Most of our manufacturing facilities are approved by major regulatory authorities USFDA, WHO-Geneva, UK-MHRA, etc. Our approach remains to identify and invest ahead of time with strategic investments in State-of-the-Art R&D and Manufacturing Infrastructure enabling us to become a quality supplier of high volume products. **Corporate Identification No: L24239AP2005PLC047518**

For more information about us, please visit <http://www.lauruslabs.com> or Contact particulars:

Pavan Kumar N
Laurus Labs Ltd.
Tel: +91 40 3980 4380/7337353848
Email: mediarelations@lauruslabs.com



DISCLAIMER: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.